Serotonin 5 Ht1A Receptor Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
5-HT1A receptors represent one of the most extensively studied serotonin receptor subtypes in the brain, playing crucial roles in mood regulation, anxiety, neuroprotection, and cognitive function[1]. These Gi/o-protein-coupled receptors are strategically positioned throughout the limbic system and brainstem, where they modulate neuronal excitability and serve as critical targets for both physiological signaling and pharmacological intervention in neuropsychiatric disorders[2].
| Property | Value |
|---|---|
| Category | Receptor neurons |
| Neurotransmitter | Serotonin (5-hydroxytryptamine) |
| Receptor | 5-HT1A (HTR1A) |
| G Protein | Gi/o |
| Brain Regions | Hippocampus, raphe nuclei, amygdala, cortex, hypothalamus |
| Expression | Both presynaptic (autoreceptor) and postsynaptic |
5-HT1A receptors exert their effects through multiple intracellular pathways[3]:
In the dorsal and median raphe nuclei, 5-HT1A autoreceptors serve as critical feedback regulators[4]:
In limbic and cortical regions, 5-HT1A postsynaptic receptors modulate circuit function[5]:
| Region | Function |
|---|---|
| Hippocampus | Memory consolidation, anxiolysis, neurogenesis |
| Amygdala | Fear extinction, emotional processing |
| Prefrontal cortex | Cognitive flexibility, decision-making |
| Hypothalamus | Stress response, neuroendocrine regulation |
5-HT1A receptor activation provides neuroprotection through multiple mechanisms[6]:
5-HT1A receptors are major targets for antidepressant and anxiolytic drugs[7]:
5-HT1A receptors play complex roles in AD pathophysiology[8]:
5-HT1A receptors are implicated in PD pathophysiology and treatment[9]:
| Drug | Type | Clinical Use |
|---|---|---|
| Buspirone | Partial agonist | Anxiety, GAD |
| Tandospirone | Partial agonist | Anxiety, depression |
| Flesinoxan | Full agonist | Depression, anxiety |
| Vilazodone | SSRI + 5-HT1A partial agonist | Major depression |
| Vortioxetine | Multimodal | Depression, cognition |
The study of Serotonin 5 Ht1A Receptor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Barnes NM, 5-HT1A receptors in neuropsychopharmacology (2020). 2020. ↩︎
Polter AM, 5-HT1A receptor function in neuronal signaling (2017). 2017. ↩︎
Sharp T, 5-HT1A autoreceptors in raphe nuclei (2015). 2015. ↩︎
Celada P, 5-HT1A receptors in prefrontal cortex (2013). 2013. ↩︎
Blier P, 5-HT1A receptors in antidepressant action (2021). 2021. ↩︎
Bara-Jimenez W, 5-HT1A and Parkinson's disease (2020). 2020. ↩︎